U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share, Trends, Industry Analysis Report By Service Type (In-House, Contract Outsourcing), By Synthesis Type, By Animal Type, By Therapeutic Category – Market Forecast, 2025–2034

The U.S. veterinary active pharmaceutical ingredients manufacturing market size is expected to reach USD 4.97 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Share, Size, Trends, Industry Analysis Report By Service Type (In-House, Contract Outsourcing), By Synthesis Type, By Animal Type, By Therapeutic Category; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The veterinary active pharmaceutical ingredients (APIs) manufacturing market focuses on the production of biologically active substances used as the core components in veterinary drugs. These APIs serve as the foundation for formulating medicines that prevent, treat, or manage diseases in animals, ensuring animal health, food safety, and productivity. The applications of these APIs extend across companion animals, livestock, and poultry, covering therapeutic categories such as antiparasitics, anti-infectives, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The manufacturing process of these APIs requires strict compliance with good manufacturing practices (GMP) to ensure purity, efficacy, and safety. The increasing focus on animal welfare, rising prevalence of zoonotic diseases, and demand for safe animal-derived food products drive the usage of veterinary APIs.

The U.S. veterinary active pharmaceutical ingredients manufacturing industry plays a crucial role in supporting the country’s large livestock and companion animal populations. The industry benefits from advanced R&D infrastructure, a strong regulatory framework set by the U.S. Food and Drug Administration (FDA), and high investments in biotechnology. Rising pet ownership, coupled with growing expenditure on animal healthcare, drives demand for high-quality APIs in the region. Moreover, the U.S. is a hub for innovation in veterinary medicine, with companies developing novel treatments and biologics.

U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report Highlights

In terms of service type, the in-house segment accounted for a major revenue share in 2024 due to its ability to offer strict control over quality, intellectual property, and regulatory compliance.

The contract outsourcing segment is projected to grow at a robust pace in the coming years, owing to veterinary pharmaceutical companies seeking cost efficiency and flexibility in API production.

Based on synthesis type, the chemical-based API segment held the largest U.S. veterinary active pharmaceutical ingredients manufacturing market share in 2024. Manufacturers produced antiparasitics, anti-infectives, and non-steroidal anti-inflammatory drugs (NSAIDs) predominantly through chemical synthesis due to their cost efficiency, established processes, and scalability.

In terms of animal type, the production animals segment dominated the revenue share in 2024 due to strong demand for veterinary medicines in cattle, poultry, and swine production.

The companion animal segment is expected to grow at a rapid pace in the coming years, owing to the increasing pet ownership.

Based on therapeutic category, the antiparasitics segment accounted for a major revenue share in 2024 due to their extensive use in both livestock and companion animals.

A few key players in the U.S. veterinary active pharmaceutical ingredients manufacturing market include Alivira Animal Health Limited, Bimeda Inc., Elanco Animal Health, Excel Industries Ltd., Fabbrica Italiana Sintetici S.p.A., Huateng Pharma, Merck Animal Health, Ofichem Group, Phibro Animal Health Corporation, Rochem International Inc., SUANFARMA, and Zoetis.

Polaris Market Research has segmented the U.S. veterinary active pharmaceutical ingredients manufacturing market report on the basis of service type, synthesis type, animal type, and therapeutic category:

By Service Type Outlook (Revenue, USD Billion, 2020–2034)

In House

Contract Outsourcing

Contract Development

Preclinical Development

Clinical Development

Contract Manufacturing

By Synthesis Type Mode Outlook (Revenue, USD Billion, 2020–2034)

Chemical-Based API

Biological API

HPAPI

By Animal Type Outlook (Revenue, USD Billion, 2020–2034)

Production Animals

Companion Animals

By Therapeutic Category Outlook (Revenue, USD Billion, 2020–2034)

Antiparasitics

Anti-infectives

NSAIDs

Others Show more